Mark Wingertzahn

Background

About Mark Wingertzahn

Proven biotechnology and pharmaceutical partner with a track record of driving innovation across nonclinical and clinical development. My hands-on approach, combined with strategic oversight, has delivered over 10 New Drug Applications (NDAs) and three first-in-class multinational drug approvals. My expertise spans diverse therapeutic areas, including rare diseases, infectious diseases, CNS, gastrointestinal disorders, metabolic health, pain management, and psychedelics, making me uniquely equipped to navigate the complexities of today’s biotech landscape. As a collaborative leader, I excel at building high-performing global teams, forging regulatory strategies, and advancing cutting-edge therapies to address unmet medical needs. My ability to integrate strategic vision with operational execution sets me apart. My track record of securing first-in-class approvals, navigating complex regulatory landscapes, and leading global teams positions me as a trusted partner for biotech organizations aiming to innovate and scale. Whether advancing novel first-in-class assets or improving upon existing therapies, I bring a unique blend of scientific and clinical expertise, leadership acumen, and adaptability to deliver meaningful inflection points and shareholder value.